Form 4: Immuneering Corp Executive Acquires 240,000 Stock Options
SEC Form 4 Filing
Brett Matthew Hall, Chief Scientific Officer of Immuneering Corp, reports acquiring 240,000 stock options on February 5, 2025.
Summary
- On February 5, 2025, Brett Matthew Hall, the Chief Scientific Officer of Immuneering Corp, acquired 240,000 stock options.
- The options have an exercise price of $1.91.
- The options vest in equal monthly installments over four years, starting February 1, 2025, and will be fully vested by January 1, 2029.
- The options expire on February 5, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation disclosure.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The granting of stock options can incentivize the executive to improve company performance, potentially benefiting shareholders.
- Employees may view the executive compensation positively or negatively depending on their own compensation and perceived fairness.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | Vesting of options commences in equal monthly installments over a four-year period. |
| 02/05/2025 | Date of transaction: Brett Matthew Hall acquired 240,000 stock options. |
| 02/07/2025 | Date of Form 4 filing. |
| 01/01/2029 | Options will be fully vested and exercisable. |
| 02/05/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.